Abstract

From 2005 to 2010, 20 consecutive patients with fully manifested neurofibromatosis type 1 (NF1) underwent elective neurofibroma resection at our institution (Departments of Plastic Surgery and of Odontostomatology). Specimens were photographed under optical microscope and confocal laser scanning microscopy (CLSM) with ultra-high accuracy of detail, including depth of field. Patients were followed up for a minimum of 4 years and up to a maximum of 12 years, postsurgery. While all nonrecurring lesions showed intense fluorescence, six of the seven lesions with absence of fluorescence under CLSM recurred at a mean of 5.5 years after surgical excision. Among the re-excised lesions, 3 were diagnosed as malignant at the subsequent removal. Despite the limitation of a small cohort, CLSM appears to be a simple and low-cost technique to differentiate forms of neurofibromas with low and high risk of recurrence and malignant degeneration.

Highlights

  • We retrospectively describe our 5-year experience in using confocal laser scanning microscopy (CLSM) to differentiate the morphological features of Schwann cells at the time of first resection of neurofibromas arising in neurofibromatosis type 1 (NF1) patients

  • Specimens were photographed under optical microscope and confocal laser scanning microscopy (CLSM) with ultra-high accuracy of detail, including depth of field

  • We retrospectively describe our 5-year experience in using confocal laser scanning microscopy (CLSM) to differentiate the morphological features of Schwann cells at the time of first resection of neurofibromas arising in NF1 patients

Read more

Summary

Introduction

We retrospectively describe our 5-year experience in using confocal laser scanning microscopy (CLSM) to differentiate the morphological features of Schwann cells at the time of first resection of neurofibromas arising in NF1 patients (study registration number: researchregistry3681). We propose that CLSM could be a simple low-cost technique to differentiate neurofibromas with low or high risk of recurrence and malignant degeneration

Report
Discussion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.